A number of studies have shown a high rate of comorbidity of obsessive compulsive disorder (OCD) and major depressive disorder (MDD), but it remains unclear whether affective episodes are primary or secondary to obsessive compulsive (OC) symptoms and whether MDD is etiologically related to OCD. We studied 26 OCD patients and 28 of their relatives to determine the effect of concomitant MDD on the symptomatology and familial aggregation of OCD. Fifteen of the 26 OCD patients (57.7%) had a history of depression. In the majority of cases (73%) OC symptoms appeared prior to the onset of depression. Although there were more females than males (9:6) with co-morbid MDD, the gender distribution was not significantly different from OCD patients without MDD (3:8). We found no differences in Y-BOCS total scores, compulsion subscores, obsession subscores or age of onset of OC symptoms between probands with MDD compared to those without. There was also no differences in the rates of other co-morbid disorders between the two proband types. The only significant difference we found was a higher morbidity for MDD in the relatives of patients with MDD compared to the relatives of patients without (36.4% verses 5.9%, p=0.04 using a 2-tailed c 2 test). There was no significant difference in morbidity for any other diagnosis, including OCD (9.1% verses 5.9%). These results suggest that the co-occurance of MDD with OCD is due to the chance co-segregation of the two disorders, rather than representing a more severe form of the disorder. A Bal1 polymorphism in the coding region of the dopamine D3 receptor gene has been shown to be associated with schizophrenia. However, no functional effect of this polymorphism has been determined. It has been hypothesized that a 5Ј upstream polymorphism in linkage disequilibrium with the Bal1 polymorphism could be the functional link between the dopamine D3 receptor and schizophrenia.
we have investigated markers located in this region, as well as 15 markers spanning the whole chromosome 13 in 248 subjects from 31 families ascertained through lithium responsive bipolar probands. No significant evidence of linkage was found in our families for markers located on 13q32 or any other region of chromosome 13. Our results do not support a role of a major locus for bipolar disorder on this genomic region. A number of studies have shown a high rate of comorbidity of obsessive compulsive disorder (OCD) and major depressive disorder (MDD), but it remains unclear whether affective episodes are primary or secondary to obsessive compulsive (OC) symptoms and whether MDD is etiologically related to OCD. We studied 26 OCD patients and 28 of their relatives to determine the effect of concomitant MDD on the symptomatology and familial aggregation of OCD. Fifteen of the 26 OCD patients (57.7%) had a history of depression. In the majority of cases (73%) OC symptoms appeared prior to the onset of depression. Although there were more females than males (9:6) with co-morbid MDD, the gender distribution was not significantly different from OCD patients without MDD (3:8) . We found no differences in Y-BOCS total scores, compulsion subscores, obsession subscores or age of onset of OC symptoms between probands with MDD compared to those without. There was also no differences in the rates of other co-morbid disorders between the two proband types. The only significant difference we found was a higher morbidity for MDD in the relatives of patients with MDD compared to the relatives of patients without (36.4% verses 5.9%, p=0.04 using a 2-tailed c 2 test). There was no significant difference in morbidity for any other diagnosis, including OCD (9.1% verses 5.9%). These results suggest that the co-occurance of MDD with OCD is due to the chance co-segregation of the two disorders, rather than representing a more severe form of the disorder. A Bal1 polymorphism in the coding region of the dopamine D3 receptor gene has been shown to be associated with schizophrenia. However, no functional effect of this polymorphism has been determined. It has been hypothesized that a 5Ј upstream polymorphism in linkage disequilibrium with the Bal1 polymorphism could be the functional link between the dopamine D3 receptor and schizophrenia.
EFFECT OF CO-MORBID MAJOR

H. Candidate Genes Posters
DNA from fourteen unrelated people with schizophrenia and fourteen with bipolar disorder have been used to screen nearly five thousand base pairs of newly identified 5Ј sequence for polymorphisms using denaturing high performance liquid chromatography (DHPLC). A total of thirteen polymorphisms have been identified in exonic, intronic and potential promoter regions.
All polymorphisms have been initially genotyped for in forty schizophrenics and matched controls to assess for complete linkage disequilibrium with the Bal1 polymorphism. After the initial screen informative polymorphisms and those that arise in regions of interest were assessed for association using the complete Cardiff schizophrenia case control sample for association to schizophrenia.
DOPAMINE D3 RECEPTOR: ANALYSIS OF THE
5ЈUTR AND 5ЈFLANKING REGIONS. Anney RJL, Rees MI, Bryan EJ, O'Donovan MC, Owen MJ, Buckland PR. Dept. Psychological Medicine, University of Wales College of Medicine, Heath Park, Cardiff, CF4 4XN, United Kingdom.
The dopamine D3 receptor (DRD3) is well documented as a candidate gene for schizophrenia and other psychiatric disorders. However, the gene is relatively poorly characterized with neither 3Ј UTR, 5ЈUTR nor the promoter region having been identified. Using 5Ј and 3ЈRACE and genomic sequencing we have identified several upstream exons that are transcribed from more than one promoter in a tissue specific manner. An additional co-located gene has also been identified. 5ЈRACE has been carried out on different tissues including brain, lymphocyte, placenta and kidney to determine 5ЈUTR sequences. The sequence was compared to the corresponding genomic sequence which was acquired by direct sequencing of a human P1 artificial chromosome clone. Using these procedures we have identified an extra eight thousand seven hundred base pairs of genomic sequence and have identified intron/exon structure for each tissue type. Multiple independent clone sequencing has been used to determine the 5Ј end of the RACE products, allowing the determination of the transcriptional start site and the promoter region.
Several additional exons have been discovered upstream of the previously described exon 1 of the DRD3 gene. Preliminary data suggests that tissue specific RNA splicing may be a feature of this gene directed by putative multiple promoters. In addition, a second gene has been identified via bioinformatics programs, which nests within the DRD3 gene. Exon 1 of this gene is located between the previously reported DRD3 exon 1 and the newly identified additional upstream exons. Background: Association between the dopamine-D3-receptor gene (DRD3) and schizophrenia has been examined in at least 30 studies, two recent meta-analyses provide support for a minor but statistically significant relationship between schizophrenia and the Bal I polymorphism (Williams et al. 1998; Dubertret et al. 1998) . In a previous case-control study from Israel, excess homozygosity of the 2-2 genotype was observed especially in a non-Ashkenazi population (Ebstein et al. 1997) , in two case-control studies from Germany no association was found (Rietschel et al. 1996 (Rietschel et al. , 1997 .
THE DOPAMINE D3 RECEPTOR (DRD3)
SER9
Objectives and Methods:
In the framework of a trilateral program between Israel, the Palestinian Authority and Germany we are recruiting Palestinian Arabs for family based studies on the genetics of schizophrenia. We now present a preliminary report of a group of 94 probands and their parents who we examined using the haplotype relative risk (HRR) design 1 for an association between schizophrenia and the D3 dopamine receptor Ser9/Gly Bal I polymorphism.
Results: No significant difference was observed in genotype frequency between schizophrenic patients and the haplotype relative risk control group. The current results are preliminary and are based on only 94 Palestinian schizophrenic triads towards our ultimate goal of recruiting 300 triads. Ebstein RP. et al. Hum Hered 47, 6-16 (1997) . Rietschel M. et al. Schizophr Res 20:181-186 (1996 Several studies have suggested a possible association of a polymorphism at the dopamine D4 receptor gene and attention-deficit hyperactivity disorder (ADHD). The allele reported to be associated with ADHD is the allele with 7 copies of the 48 bp repeat in the third exon. In this study we extend our study of the dopamine D4 gene and ADHD by testing for linkage using two additional polymorphisms in the dopamine D4 receptor gene (the mononucleotide repeat in the first intron and the 12 base pair repeat in the first exon) and a polymorphism in the closely linked gene, tyrosine hydroxylase. We tested for linkage using the transmission disequilibrium test in a sample of 82 families with an ADHD proband. We also searched for two previously reported deletions, a 13 bp and a 21 bp deletion in the first exon, but we did not observe these deletions in our sample. We examined the haplotypes of three polymorphisms of the D4 receptor gene and observed biased transmission of two of these haplotypes. Our findings further support the role of the dopamine D4 gene in ADHD. Dopamine has long been hypothesised to be involved in the pathogenesis of schizophrenia and its role in Parkinsons's disease is well documented. The dopamine D2 receptor is a major site of action of drugs used in the treatment of both disorders. Arinami et al. (1997) sequenced the dopamine receptor 2 (DRD2) gene in Japanese individuals and identified a novel polymorphism: a single cytosine deletion at position -141 disrupting a BstN1 restriction site with a frequency of 0.22 in their control group. They then found a strong association with this polymorphism and schizophrenia (pϽ0.001) with an odds ratio of 0.60 in a Japanese population. We have attempted to verify their results by repeating their analysis on a sample of Scottish schizophrenics and controls. We then combined our data with those from another British sample recruited using similar procedures. The total combined sample size is 439 schizophrenics and 437 controls. We obtain a significant association -p = 0.02 with an odds ratio of 1.41. We subsequently genotyped a series of English and Scottish Parkinson's (n=250) but did not find any significant association. Thus, schizophrenia but not Parkinson's disease is weakly associated with the -141 polymorphism. This is the reverse of Arinami et al.'s finding. We hypothesise that, if this is not a chance result, than differing linkage disequilibrium arrangments in the two populations may account for the difference. Evidence from adoption, family, and twin studies suggest that genetic factors are important in AttentionDeficit/Hyperactivity Disorder (ADHD). A 10-repeat VNTR in the dopamine transporter (DAT1) has been associated with ADHD in 4 independent samples (Cook et al, 1995; Gill et al, 1997; Waldman et al, 1996; Daly et al, 1999) . We examined this polymorphism in 83 trios (56 families) consisting of a proband with DSM-IV Combined Type ADHD and both parents. The 9-repeat allele was transmitted 45 times, and not-transmitted 44 times; the 10-repeat allele was transmitted 121 times and not-transmitted 122 times. This HRR resulted in a chi square = 0.015, df=1, p=.90 (TDT =.02, p=.89). HRR analysis in 56 unrelated proband was also negative, with a tendency toward more frequent transmission of the 9-repeat allele (transmitted 35; not-transmitted 26; chi square = 1.82, p=.18; TDT = 2.08, p=.15). These data do not support the reported association between the 3Ј untranscribed DAT1 10-repeat allele and ADHD. The involvment of dopamine in the aetiology of schizophrenia is suggested by number of neurobiological and pharmacological data. The gene which codes for dopamine receptor D2 (DRD2) is considered as one of the most relevant candidate genes in schizophrenia, in view of antipsychotic drugs' biological and pharmacological features. A negative allelic association study was reported between a deletion/insertion variant (−141C Ins/Del) in the 5Ј-promoteur region of the DRD2 and schizophrenia, but this result was not confirmed by others. This was of particular interest since the deletion is functional, in that it is associated with a reduced basal level of receptor expression (43% to 21%).
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LACK OF ASSOCIATION BETWEEN
We thus reaxamined this association controling for one of the major bias of association studies (i.e. statification bias) and one of the major limitation of parametric linkage studies (i.e. estimating the unknown characteristics of the type of inheritability), using the haplotype-based haplotype relative risk method (HRR) and the transmission disequilibrium test (TDT). We searched for non-randomly transmitted alleles at the −141C Ins/Del polymorphism in 50 french trios containing the schizophrenic proband and both parents.
We found no excess of transmission of the −141C Del allele from the parents to the affected children, using the haplotype relative risk design (C2=0.06, df=1, p=0.81). The transmission disequilibrium test also showed no evidence for linkage between this functionnal polymorphism and schizophrenia (C2=0.06, df=1, p=0.81). The present analysis do not support a major role of −141C Ins/Del polymorphism of the DRD2 gene in the susceptibility to schizophrenia. Prior studies have shown attention deficit hyperactivity disorder (ADHD) to be associated with the dopamine D4 (DRD4) and dopamine transporter (DAT) genes. To replicate these findings and to examine the combined effects of these loci, we recruited 43 nuclear families containing 86 parents and 78 children. These families were assessed for ADHD and their DNA was genotyped for DRD4 and DAT alleles. A two-stage procedure tested for association between ADHD status and the DAT-480 and DRD4-7 alleles. First, we modeled the association between affection status and the alleles of interest using a standard logistic model. To increase efficiency or to test for interactions, other associated alleles, covariates, and interaction terms can also be incorporated into the model at this stage. Second, we derived score statistics for the association parameters of interest. The distribution of the score statistic under the null hypothesis of no linkage and no association was computed conditional on the parental marker alleles, treating the transmitted marker alleles as random. We found a significant association for the DRD4-7 allele (p=.03) and a nearly significant result for the DAT-480 allele (p=.06). We are currently testing for the joint effects of these alleles in a larger sample. The association between ADHD and DRD4 is a robust finding now confirmed in several laboratories. Because our sample is relatively small, the negative results for DAT and its potential interaction with DRD4 must be viewed with caution. Two german case-control studies (Sander et al., 1997; Schmidt et al., 1998) showed that the A9 allele may increase the risk for severe withdrawal symptoms for alcohol-dependent patients who stop drinking (specially withdrawal seizures and delirium). These studies were consistent as one was retropective and quantitative, and the other prospective and qualitative.
A FAMILY BASED ASSOCIATION STUDY OF THE DOPAMINE D4 AND THE DOPAMINE TRANS-PORTER GENE
FURTHER EVIDENCE FOR THE
We analysed lifetime withdrawal symptoms in 120 french alcohol-dependent patients and 65 control subjects assessed with the DIGS, in order to specify which symptoms and/or patients may be more specifically involved and to compare the distribution of the DAT1 polymorphisms in matched controls.
In our sample, the A9 allele was more frequent in patients who had at least once withdrawal seizure or delirium (23/62 versus 11/58) (p=0.028), showing the same trend as did the first study. There was a significant linear trend for increased number of withdrawal symptoms in patients with the A9 allele (p=0.03). Furthermore, patients who took alcohol at least once in order to reduce withdrawal symptoms were more frequent in the group of patients who have the A9 allele (p=0.027). Although the distribution of symptoms is not superimposable for the two groups (with versus without the A9 allele), no specific symptom (or group of symptoms) was found increased in one group. Interestingly, the frequency of the A9 allele in the group of 65 healthy controls (without alcohol abuse or dependence) matched for sex and origins (54%) was intermediate between alcohol-dependent with withdrawal complications (71.4%) and those without such symptoms (42.3%), addressing the question wether the A9 allele is a risk factor or the A10 allele is a protective factor against complicated withdrawal.
In conclusion, the role of the A9 allele of the DAT gene in withdrawal complications is replicated in this independent sample, probably for severity of symptoms rather than for a specific type of symptom (seizures and delirium are generally considered as the most severe symptoms of withdrawal). A role for the dopamine transporter (DAT) in bipolar disorder is implicated by several lines of pharmacological evidence, as well as suggestive evidence of linkage at this locus, which we have previously reported. In the process of screening the introns and exons of DAT for possible functional mutations, we have identified a number of single nucleotide polymorphisms (SNPs) that span the gene from the distal promoter through exon 15. Of the 34 SNPs that are suitable for linkage disequilibrium studies, 5 have been analyzed thus far using allele-specific PCR to generate haplotypes in a sample of 30 triads. The haplotyped marker in the exon 9 region was analyzed using the ETDT program and shown to be in linkage disequilibrium with bipolar disorder (allele-wise TDT p=0.044, genotype-wise TDT p=0.0097). These data replicate our previous finding of linkage disequilibrium to a marker approximately 15 kb away in a largely different family set, and provides further evidence for a role of DAT in bipolar disorder. Multiple research groups have demonstrated association and linkage between the dopamine receptor D4 gene (DRD4) and attention-deficit/hyperactivity disorder (ADHD). ADHD is related to a variety of executive function (EF) deficits, including inattention and impulsivity, and difficulties in organization and planning. In this study, a clinic-referred sample of children aged 6 to 16 was genotyped for a 48-bp repeat polymorphism in exon III of DRD4 and administered a battery of EF measures. All of the participants met DSM-IV criteria for ADHD, and many also met criteria for Oppositional Defiant Disorder, Conduct Disorder, and/or internalizing disorders. Following previous studies of DRD4 and ADHD, the 7-repeat allele was considered the high-risk allele. The EF measures included a Continuous Performance Test, the ReyOsterreith figure, a letter cancellation test, a word fluency test, the Stroop Test of Interference, and Trails A and B. We regressed participants' EF measure scores on their number of DRD4 high-risk alleles (i.e., 0, 1, or 2). DRD4 was associated with performance on a number of EF measures (viz., Rey-Osterreith organization scores, Continuous Performance Test response time, word fluency -total words generated, and time to complete Trails A) and accounted for 3-6% of the variance in these EF measures. These results suggest that association of DRD4 and ADHD is not limited to parents' ratings of DSM-IV symptoms but extends to laboratory measures. In addition, use of these EF measures in addition to symptom ratings may provide incremental evidence for association and linkage between DRD4 and ADHD. Association studies of the dopamine D3 receptor gene (DRD3) in schizophrenia have reported conflicting results. There were suggestions that the association is salient only in specific subgroups of schizophrenia; male patients, patients with family history, non-responders to neuroleptics, etc. The present study aims at examining the association between DRD3 MscI polymorphism and schizophrenia in ethnically homogenous Korean population. We genotyped 80 schizophrenic patients (DSM-IV) and 71 normal controls. We also investigated the association between DRD3 MscI polymorphism and subgroups characterized by; age at onset (age at initiation of neuroleptic treatment), family history of schizophrenia in their second degree relatives, and deficit syndrome (Schedule for the Deficit Syndrome). No significant difference in allelic ( 2 =1.95, df=1, p=0.16) or genotypic distribution ( 2 =3.73, df=2, p=0.16) was found between the schizophrenic patients and controls. The differences were still not significant when the patients were divided into male vs. female, early-vs. late-onset, familial vs. non-familial, or deficit vs. non-deficit subgroups. The frequencies of homozygosity in patients as a whole ( 2 =0.036, df=1, p=0.85) and any of the subgroup were not significantly different from that of the control group. The association between DRD3 MscI polymorphism and schizophrenia was not replicated in Korean population. The 48-bp repeat polymorphism within the third cytoplasmatic loop of the DRD4 receptor was analyzed by PCR in healthy controls and schizophrenic patients. Out of 1360 subjects all numbers of repeats between 1 and 10 were found resulting in 25 genotypes. Schizophrenic male with an age of onset of Ն25 years (pϽ0.02), or without clinical remission (pϽ0.02) carried more frequent the longer alleles (Ն×5), whereas schizophrenic female with an age of onset Յ25 years (pϽ0.02) carried more frequent the shorter alleles (Յ×4) and all genotype combinations coding up to a length of 4 × 48-bp or less (pϽ0.03) compared to all controls. Catatonic patients carried more frequently the combined alleles ×2 and ×3 compared with all other schizophrenics (pϽ0.001, OR: 3.6, Cl: 1.7-7.7). Sequencing of this region in a subgroup of clozapine treated patients revealed previously unknown variants.
EVIDENCE FOR LINKAGE
ASSOCIATION OF DRD4 AND MEASURES
LACK OF ASSOCIATION BETWEEN
CHARACTERIZATION AND THERAPEUTIC REL-EVANCE OF INCOMPLETE TANDEM REPEATS IN THE
Individuals carrying the 9-repeat allele or shorter of the 17-bp repeat of the second intron of the 5-HTT had a 5.0 fold increased risk for schizophrenia (pϽ0.005, Cl: 1.5-17.2), whereas individuals those with the 10-repeat allele or longer might be protected (pϽ0.005, OR: 0.2, Cl: 0,1-0,7). In conclusion the data might indicate a contribution of these hypervariable regions to the pathophysiology and the response to drug therapy of schizophrenia. This study is supported by BMBF grants 01EC9408, 01ZZ9511.
AN ASSOCIATION STUDY BETWEEN ATYPICAL
PSYCHOSES AND DOPAMINE D2 RECEPTOR GENE Koh J, Yoneda H, Sakai J, Inada Y, Himet A, Kinoshita Y, Akabame K, Sakai T. Dept. of Neuropsychiatry, Osaka Medical College.
Genetic contributions to the ethiology of some psychoses have been generally well accepted. Atypical psychoses was defined as the fourth endogenous psychosis in the areas where the three major psychoses overlap by MITSUDA (1942 MITSUDA ( , 1954 on the basis of his clinicogenetic studies. Atypical psychoses were considered as heterogeneous entity, consisting of three types (type 1, 2 and 3) which differed in genetic background and clinical features (TOYODA et al, 1988) .
We conducted an association study between atypical psychoses and dopamine D2 receptor gene (DRD2) using TaqIA RFLP, Ser/Cys polymorphism, A-241G polymorphism and -141C Ins/Del polymorphism.
We studied 65(22male, 43female mean age±SD: 42.3±13.3) atypical psychoses and 103(49male, 54female, mean age±SD: 33.6±10.9) controls. The diagnosis was made according to the diagnostic criteria (TOYODA et al, 1988) on the basis of MITSUDA's concept. 37(13male, 24female, mean age ±SD: 41.5±11.1) patients were subclassified as type 1 by their clinical features. We also conducted an association study between Type 1 atypical psychoses and these candidate genes.
We found the positive association between A-241G polymorphism and Type 1 atypical psychoses (*pϽ0.05, Odds Ratio: 1.22). This polymorphism is not functional site. We need further investigation to confirm this result. Sequential reverse transcription and quantitative polymerase chain reaction of the dopamine D3, D5 receptor mRNA were used to investigate the expression of dopamine receptors in human peripheral blood lymphocyte to define whether or not the dopamine receptors of peripheral lymphocytes can be the peripheral markers of schizophrenia. The total numbers of subject were 87 schizophrenic patients. Among them, 44 were chronic schizophrenics who had been taking antipsychotic drugs for more than 3 years, 28 drug-free schizophrenics who had not been taking antipsychotic drugs for more than 3 months, and 15 naïve schizophrenic patients who had no experience taking antipsychotic drugs. For controls 31 age and sex matched healthy persons were enrolled. The mutant of dopamine D3, D5 receptor were used as an external and beta-actin(.A) was used as an internal control to evaluate the expression level of the dopamine D5 receptor mRNA. The results are as follows 1. D3 dopamine receptor mRNA expression of peripheral lymphocytes was significantly increased in drug-free schizophrenics compared to controls and chronic schizophrenics. There was no difference between controls and chronic schizophrenics. A few naïve schizophrenics also revealed increased D3 and D5 dopamine receptor mRNA expression, but without statistical significance. 2. After antipsychotic medication, dopamine receptors of lymphocytes were increased after 2 weeks, with a decreasing tendency after 8 weeks after.
CHANGE OF DOPAMINE RECEPTOR
3. Drug-free patients were divided into two groups according to dopamine receptor expression in controls to evaluate the significance of increased dopamine receptor expression. The group of patients with increased dopamine receptor expression had the following clinical characteristics.
1) more severe psychiatric symptoms 2) poor pharmacological response to medication; 3) severe extrapyramidal side effects after pharmacological treatment.
These results revealed that increased expression of dopamine receptor in peripheral lymphocyte has clinical significance for subgrouping and prognostication. These findings suggest that dopamine receptors of peripheral lymphocytes may represent dopamine receptors of the brain, even if the location cannot be determined. Mesolimbic dopaminergic projections can make subjects pursue the novelty-seeking behavior. Two independent investigations (Ebstein et al 1996; Benjmin et al 1996) reported an association between dopamine D4 receptor gene (DRD4) and novelty seeking. But subsequent studies did not replicate these findings. Since Ebstein et al (1996) showed that the NS score was significantly associated with an exonic polymorphism, the 7 repeat allele at DRD4, it is interesting to examine the relationships of NS to DRD4 in the absence of 7-repeats allele in Chinese Han. We collected 130 Han criminals from Taipei Jail to test the association between NS and DRD4 individually and as haplotypes. All the unrelated subjects gave informed consent and completed the Chinese version of novelty seeking scale. The methods of genotype were described by Catalano et al (1995) and by Lichter et al (1993) . All the subjects were divided into three groups, Low NS, Middle NS and High NS, according to the total scores of NS. There were significant differences observed between the Low and High NS groups on the genotype and allele frequencies of exon 3 polymorphism of DRD4. Comparing for the haplotype frequencies of exon 1 and exon 3, there were also significant differences between the low and high NS groups. Moreover, we further divided the subjects into four groups based on the genotpes of VNTR at DRD4, including 2/2, 2/4, 4/4 and 4/(Ͼ4) groups. We found that there was a significant difference on NS score among the four groups. The results support that DRD4 is associated with novelty seeking behavior in Chinese Han male criminals. Many previous family, twin and adoption studies have shown that the familial nature of alcoholism is partly due to genetic factors. On the other hand, some molecular studies suggest that dopaminergic receptors genes may be involved in the susceptibility to alcoholism, particularly the A1 allele of the D2 dopaminergic receptor (DRD2). Alcoholism is a heterogeneous disease, it is thus necessary to isolate subgroups of patients with a higher genetic risk, for example with regard to personality dimensions.
DRD4 IS ASSOCIATED WITH NOVELTY-SEEK
ASSOCIATION BETWEEN THE
In this view, the purpose of this study was to compare the Temperament and Character Inventory scores and the Taq1 DRD2 polymorphism of 44 (15 women and 29 men) alcohol-dependent patients.
The A1 allele was found in 26 patients (59.1%, with 9 women and 17 men). The reward dependence (RD) score was the only significantly different dimension between the two groups, with higher scores in A1+ patients (mean scores 15.9 (SD=2.9) versus 13.8 (SD=3.7), p=0.05, t-test). Precisely, RD is a temperament dimension viewed as a heritable trait in the maintenance or continuation of ongoing behaviors, and high RD reflects a need for constant reassurance and positive reinforcement. We also performed an analysis of variance (ANOVA) to test the impact of the A1 allele on the RD score taking into account the gender effect, and found a more significant interaction (F=4.25, p=0.04).
In conclusion, if the RD score appears to be associated with the presence of A1 allele of the DRD2 in alcoholic patients, it seems necessary to take into account the gender effect in future studies.
NO ASSOCIATION BETWEEN TWELVE-NUCLEO-
TIDE REPEAT POLYMORPHISM OF D4 DOPAMINE RECEPTOR GENE AND NEUROLEPTIC TREATMENT RESPONSE IN TAIWANESE SCHIZOPHRENIC PATIENTS. Liu CM, Lin MW, Hwu HG. Department of Psychiatry, College of Medicine, National Taiwan University, Taipei, Taiwan.
Disturbance in dopaminergic transmission have been implicated in the etiology of schizophrenia. The pharmacodynamic effect of neuroleptics has also been in the blockade of dopamine receptor. We collected 96 DNA samples of DSM-IV schizophrenic patients from a prospective longitudinal psychopathology study of schizophrenia in Taiwan. Neuroleptic treatment response was determined according to the extent of positive symptom subsided over a period. There were 49 patients in good treatment response group, 47 in poor treatment group. Genotype of the 12-bp repeat polymorphism of DRD4 was determined with polymerase chain reaction and agarose gel electrophoresis. Genotypic and allelic frequencies were compared among the two groups using the chi-square test. Twenty-nine (59%) good treatment response schizophrenic patients and 32 (68%) poor treatment response were A1 (two 12-bp repeat) homozygotes. Two (4%) good treatment response schizophrenic patients and one (2%) poor treatment response were A2 (one 12-bp repeat) homozygotes. There was no significant difference in allelic and genotypic distributions among the two groups. Our data do not support an association between neuroleptic treatment response in schizophrenic patients and any specific allele of the 12-bp repeat polymorphism of DRD4.
ASSOCIATION STUDY OF SCHIZOPHRENIA
SPECTRUM DISORDERS AND DOPAMINE D3 RECEP-TOR GENE. Meszaros K, Lenzinger E, Hornik K, Fü rdeder T, Stompe T, Willinger U, Heiden A, Fathi N, Gerhard E, Fuchs K, Sieghart W, Kasper S, Aschauer HN. Department of General Psychiatry, University of Vienna, Austria.
Alterations in the dopamine neurotransmission have been hypothesized to play a role in the etiology of schizophrenia. We considered the dopamine D3 receptor gene on chromosome 3 as a candidate gene for an association study. Method: We compared PCR-based genotyped markers for native Austrian healthy controls (n = 120) and patients (n = 95) with schizophrenia and schizophrenia spectrum disorders. Patients were diagnosed by consensus according to DSM-IIIR using the SADSLA, an unstructured psychiatric interview and a family history evaluation completed for each individual. Fisher's exact test was used to evaluate possible differences between the groups in frequencies of sex, alleles and genotypes and the distributions of homo-and heterozygotes. Results: We could not find any statistically significant differences in the allele and genotype distributions of the DRD3 receptor gene, but a trend for an association with DRD3 homozygosity. This excess appears to be more marked in the group of schizoaffectives. Comparing only schizoaffectives to controls with regard to differences in homozygosity gives a p-value of 0,022. There seems to be some evidence that distribution of DRD3 in schizoaffectives differs from that in other schizophrenics.
ASSOCIATION STUDY OF BIPOLAR DISORDER
WITH CANDIDATE GENES INVOLVED IN DOPAMI-NERGIC NEUROTRANSMISSION. Muglia P, Macciardi F, Basile VS, Parilch S, Kennedy JL. Neurogenetics Section, CAMH, University Of Toronto, Canada.
Family, twin and adoption studies have shown strong evidence for the involvement of genetic factors in the susceptibility to develop the bipolar disorder. Several lines of evidence indicate the dopaminergic (DA) system genes as candidates in bipolar disorder. The mesocorticolimbic dopaminergic system, which innervates limbic structures such as the accumbens, amygdala, ventral hippocampus, and prefrontal cortex, supports a variety of behaviours related to emotions. In order to perform an association study of DA genes in bipolar disorder we studied the DA receptor D3 gene (DRD3) and dopamine receptor D4 gene (DRD4). Both genes are highly expressed in the mesocorticolimbic DA system and their alleles code for receptor variants having small but significant different biological properties invitro. DRD3 genotypes were performed on 147 triads families containing probands with DSM-IV bipolar disorder. Statistical analysis, using extended Transmission Disequilibrium Test, in 102 informative trios has shown no evidence of linkage disequilibrium between the DRD3 alleles and bipolar disorder ( 2 =0.627; p=0.42). Also the preliminary results of the genotyping of the 48-bp repeat of DRD4 in 36 bipolar trios have shown no association between DRD4 and bipolar disorder ( 2 =1.6; p=0.42). These results indicate that the two genes do not show increased transmission of any of their alleles. Further analyses examining different genes in the DA system and narrower phenotypes will be undertaken in the future. Phonological coding dyslexia (PCD) is a geneticallycomplex developmental disorder characterized by difficulty processing the phonetic (sound) units of language despite normal intelligence. We have begun testing markers within or near candidate PCD genes for linkage (parametric LOD score method and SIBPAL affected-sibpair method), and/or association (family-based AFBAC method). The candidate genes being assessed are: gammaaminobutyric acid (GABA) receptor genes GABRA1, GABRA5, GABRB1, GABRB2, GABRB3 and GABRG2, dopamine receptor genes DRD1, DRD2, DRD3, DRD4 and DRD5, and the dopamine transporter gene DAT1. Our sample consists of 83 nuclear or extended kindreds (797 people) with at least two PCD individuals diagnosed by psychometric testing Highly suggestive evidence for linkage was found with marker D11S1363 at 11p15.5, 5cM telomeric to DRD4 (maximum LOD = 2.2 under a dominant reduced penetrance model; SIBPAL p value = 0.0041). Association was not detected with D11S1363, however tests for association with a marker located right at the DRD4 locus have yet to be performed. Evidence for both linkage and association was found with a marker within the DRD5 locus at 4p15.3-p15.1 (maximum LOD = 1.3 under a recessive reduced penetrance model; SIB-PAL p value = 0.071; AFBAC p value = 0.019). Finally, there was evidence for association (but not linkage) with marker D5S529 at 5q32-q33 (AFBAC p value = 0.027), located 0.5 cM centromeric to the GABRB2/GABRG2 cluster. In conclusion, neurotransmitter receptor genes appear to influence susceptibility to PCD, suggesting a relationship between these genes and the atypical brain development and function associated with dyslexia. There is a well-documented overlap with Tourettes Syndrome (TS), a dopaminergically-mediated neuropsychiatric disorder. Additional support for involvement of the dopamine system in OCD comes from the observed efficacy of neuroleptics in the treatment of this condition. Thus OCD may well be mediated by genetic factors in the dopamine system. The dopamine D4 receptor gene has been implicated in OCD in published reports (Cruz et al, 1997; Billett et al, 1998) , with an increased frequency of the 7-repeat alleles observed. Method: We investigated the DRD4 exon III 48 bp repeat polymorphism in a carefully characterized sample of 51 probands with parental controls. Allele transmission was analyzed using the extended TDT statistic. Results: There was a non-significant trend towards increased transmission of the 7-repeat alleles of the 48 bp repeat polymorphism. The aim of our study was to test association of dopamine D3 (DRD3) and D4 (DRD4) receptor gene polymorphisms with tardive dyskinesia (TD) in schizophrenic patients and controls. TD is a severe side effect of antipsychotic medication characterized by abnormal involuntary movements with an incidence of up to 50% of treated schizophrenic patients. 50 schizophrenic patients with stable TD, 109 healthy controls and a representative sample of 86 schizophrenic patients with and without TD were recruited. For DRD3 a biallelic Ser9Gly polymorphism was genotyped, for DRD4 a multiallelic 48 bp VNTR polymorphism. For statistical analysis Fisher's exact test was calculated.
LINKAGE AND ASSOCIATION ANALYSES
TDT ANALYSIS OF THE
When testing for association no significant result was found for DRD3. DRD4 differed significantly in allele and genotype distribution, when the most frequent allele (allele 4, p=1.548e-05) and genotype (4/4, p=4.764e-05) were tested against all others. This difference results from an overrepresentation of allele 4 in the TD group, in the control group alleles are more evenly distributed, the distribution in the schizophrenia group is between TD and controls.
An association between TD and DRD3 as previously published by Steen et al. (1997) could not be replicated in our study. Regarding DRD4 a trend in the allelic distribution from controls via schizophrenic patients to schizophrenic patients with stable TD could be observed. 4 , Institute of Psychiatry, London, UK. ADHD is one of the commonest causes of disruptive behaviour in childhood, affecting 2-5% of school age children. The aetiology of the disorder is unknown but family and twin studies indicate substantial genetic influences. Research aimed at the detection of susceptibility genes has so far focused on association studies with genes involved in the regulation of dopamine neurotransmission. Recent studies report positive associations between ADHD and polymorphisms in or near DRD4, DAT1, DRD5 and DBH. Such a cluster of findings with genes which all impact upon the same neuronal pathways raises expectations that hyperactive behaviour may be explained by relatively simple genetic mechanisms. However, at this stage, none of the findings yet reach the level of a confirmed genetic risk factor for ADHD. In this study we attempt to replicate the reported associations in 100 Turkish ADHD trios. Probands were diagnosed under DSMIV criteria for ADHD following the K-SADS interview, and cases with significant comorbidity excluded. The SNAP, Conner's teachers and parents, CBCL, TRF and Du Paul scales were administered.
A FAMILY-BASED ASSOCIATION STUDY OF
We found no evidence for association with either the DAT1 (HHRR chi square = 0.13, NS) or DRD4 (HHRR chi square = 0.043, NS) VNTRs. Preliminary analysis of DBH showed slight distortion of allele transmission with a microsatellite close to the gene, but we have yet to analyse data from the RFLP marker reported by Daly et al. DRD5 showed a trend for excess transmission of the same allele as reported by Daly and colleagues (TDT chi square = 2.25, df=1, p = 0.06 one-tailed test).
a set of between-family association analyses, we regressed symptom scores on the number of DRD3 serine alleles (viz., 0, 1, or 2) and found that ODD and CD symptom levels increased with the number of serine alleles. In a set of within-family association analyses of genetically discordant siblings, we found that the sibling with the greater number of DRD3 serine alleles had highest levels of ODD and CD symptoms. We also used an extension of the Transmission Disequilibrium Test (TDT) designed to examine linkage disequilibrium between a candidate gene and both categorical and continuous traits, as well as heterogeneity linkage disequilibrium. For the overall sample, there was no evidence for linkage disequilibrium between DRD3 and childhood disruptive disorder symptoms. There was evidence suggesting a strong sex difference, however, such that there was linkage disequilibrium between DRD3 (serine) and disruptive disorder symptoms in girls but not in boys. These results suggest that DRD3 is related more strongly to childhood antisocial behavior (i.e., symptoms of ODD and CD) than to ADHD, and that this relation may be stronger in girls than in boys.
